Apigenin inhibits in vitro and in vivo tumorigenesis in cisplatin-resistant colon cancer cells by inducing autophagy, programmed cell death and targeting m-TOR/PI3K/Akt signalling pathway

Xiaping Chen¹, Hang Xu², Xinhua Yu³, Xue Wang⁴, Xiaohu Zhu³, Xiaofeng Xu⁵

¹Department of Scientific Research, Taihe Hospital (Hubei University of Medicine), Shiyan, Hubei 442000, China; ²Department of Physical Examination Center, Taihe Hospital (Hubei University of Medicine), Shiyan, Hubei, 442000, China; ³Department of Orthopaedic Rehabilitation ward, Taihe Hospital (Hubei University of Medicine), Shiyan, Hubei, 442000, China; ⁴Department of Obstetrics and Gynaecology, Taihe Hospital (Hubei University of Medicine), Shiyan, Hubei, 442000, China; ⁵Department of Pharmacy, Renmin Hospital (Hubei University of Medicine), Shiyan, Hubei, 442000, China.

Summary

Purpose: Colon cancer is one of the deadly malignancies and the second most frequent cancer in the world. The development of drug resistance and dearth of the viable drug options forms an obstacle in the treatment of colon cancer. Herein, the anticancer potential of Apigenin was examined against cisplatin-resistant colon cancer cells.

Methods: The proliferation rate of the cisplatin-resistant colon cancer cell line HT-29 was assessed by WST-1 assay. Autophagy was detected by electron microscopy. Apoptotic cell death was analysed by propidium iodide (PI) staining. Cell cycle analysis was performed by flow cytometry. Protein expression was determined by immuno blotting. Xenografted mice models were used for in vivo evaluation of Apigenin.

Results: The results showed that Apigenin could considerably inhibit the proliferation of colon cancer cells. The anticancer activity of Apigenin against the HT-29 colon cancer cells was found to be due to induction of autophagy and apoptosis. The Apigenin-triggered apoptosis and autophagy were also linked with alteration in the apoptosis and autophagy-related protein expression. Furthermore, it was found that Apigenin could inhibit the m-TOR/PI3K/AKT signalling pathway in the cisplatin-resistant colon cancer cells. The effects of Apigenin were also examined in vivo in xenografted mice models and it was revealed that Apigenin inhibited the growth of xenografted tumors.

Conclusions: Taken together, these results indicate that Apigenin could inhibit the growth of cisplatin-resistant colon cancer cells in vitro and in vivo and may be used for the improvement of therapy of colon cancer.

Key words: autophagy, apoptosis, cell cycle, apigenin, colon cancer

Introduction

Colon cancer causes tremendous mortality world over. The incidence of colon cancer has increased at an alarming rate and is now the second most widespread type of cancer in the world and fifth in USA [1,2]. The different adverse effects of the chemotherapeutic agents and minimal choice of the effective drugs create limits in the treatment of colon cancer [3]. Recent studies have shown that molecules derived from edible plants can be used as safer anticancer drugs [4]. Plants form a ubiquitous source of flavonoids and it is believed that diets that contain high amounts of flavonoids reduce...
the risk of cancer development [5]. Pharmacological studies have shown that flavonoids possess a number of bioactivities, including anticancer activity [6]. Several of the flavonoids have been reported to halt the proliferation of cancer cells and thus may be considered essential for the development of novel therapies for colon cancer [7]. Apigenin is an important flavonoid that has been shown to inhibit the growth of several types of cancer cells [8,9]. However, the anticancer effects of Apigenin against the cisplatin-resistant colon cancer cells have not been investigated and the underlying mechanism is still not known. It was found that Apigenin could suppress the growth of cisplatin-resistant colon cancer. The anticancer effects of Apigenin were found to be related to induction of autophagy and programmed cell death (apoptosis).

Methods

Cell lines and culturing conditions

The cisplatin-resistant colon cancer cell line HT-29S was procured from American Type Culture Collection. The cells were maintained in Dulbecco’s modified Eagle’s medium in CO₂ incubator (Thermo Scientific) at 37°C with 98% humidity and 5% CO₂.

WST-1 assay of cell proliferation

Apigenin’s anticancer activity was assessed in cisplatin-resistant colon HT-29 cell line by WST-1 assay. In brief, the colon cancer cells were cultured at a density of 2.5×10⁵ cells/well in 96-well plates and subjected to treatment with varied concentrations of Apigenin. This was followed by incubation of the colon cancer cells with WST-1 for 3 h at 37°C and the proliferation rate was determined by assessing the absorbance at 450 nm. Cell morphology was also examined by phase-contrast microscopy as described previously [14].

Electron microscopy

The effects of the natural flavonoid Apigenin on the cisplatin-resistant colon cancer cells were examined by electron microscopy. Firstly, the colon cancer cells were administered 0, 20, 40 and 80 µM Apigenin for 24 h. The cells were then collected by trypsinization and washed with DMEM medium, which was followed by fixation in glutaraldehyde (2%) in phosphate buffer (0.1 M). The cells were then post-fixed in osmium tetroxide (1%). This was followed by treatment of the cells with ethanol and embedding in resin. Thin sections were then cut with the help of an ultramicrotome and subjected to electron microscopy.

Propidium iodide staining for the detection of apoptosis

PI staining was employed for the detection of apoptosis. Firstly, the cisplatin-resistant colon cancer cells (0.6×10⁶) were grown in 6-well plates. Following an incubation period of around 12 h, the cisplatin-resistant colon cancer HT-29 cells were subjected to Apigenin treatment for 24 h at 37°C. The cell cultures were then centrifuged and the pellets were washed with phosphate buffered saline (PBS). Next, the cells were stained with PI, centrifuged and PBS-washed. Finally, the nuclear morphology of the stained cells was examined by confocal microscopy.

Western blotting

To determine the expression of the selected proteins in the Apigenin-treated cisplatin-resistant colon cancer cells, the cells were subjected lysis with RIPA buffer and the protein content of each lysate was estimated by bicinchoninic acid (BCA) assay. The samples were then loaded on SDS-PAGE. The gels were then transferred to nitrocellulose membranes and subjected to treatment with primary antibody at 4°C for 24 h. Following this, the membranes were incubated with HRP-conjugated secondary antibody for 50 min at 25°C. Enhanced chemiluminescence reagent was used to visualise the protein bands.

In vivo study

Apigenin was also evaluated for its anticancer in vivo in xenografted mice. In brief, 4-week-old mice (nude, BALB/c) were maintained in the animal house as per the NIH guidelines. The mice were then injected with 5×10⁶ HT-29 cells subcutaneously at the left flank. The mice in each group (n=5) were injected intraperitoneally with DMSO (0.1%) dissolved Apigenin and diluted with 100 µL normal saline at 35 mg/kg and this was taken as the first day of the experiment. Apigenin was given to the xenografted mice thrice a week while the control mice were given DMSO (0.1%) in normal saline only. At the end of 6 weeks, the mice were euthanized, and the tumors were removed and used for analysis.

![Figure 1. Chemical structure of Apigenin.](image-url)
Statistics

Data are shown as mean±SD. Statistical analyses were done using Student’s t-test with GraphPad prism 7 software. P values<0.05 were considered as statistically significant.

Results

Growth inhibitory effects of Apigenin in colon cancer cells

To confirm the antiproliferative effects of Apigenin, the WST-1 assay was performed (Figure 1). Apigenin showed significant antiproliferative effects on the cisplatin-resistant colon cancer cells which were found to be dose-dependent (Figure 2). The IC_{50} of Apigenin against the HT-29 cisplatin-resistant colon cancer cells was 30 µM. In addition, it was found that the anticancer effects of Apigenin on the colon cancer cells were concentration-dependent. Furthermore, it was observed that Apigenin caused nuclear condensation, membrane shrinkage and blebbing of the HT-29 cells (Figure 3).

Induction of autophagy and programmed cell death in colon cancer cells by Apigenin

Electron microscopic analysis of Apigenin-treated cisplatin-resistant colon HT-29 cells revealed that Apigenin treatment prompted the development of autophagosomes in the colon cancer cells, indicating that Apigenin induces autophagy (Figure 4). In addition, Apigenin also caused shrinkage of the nuclei of HT-29 cells, suggestive of apoptosis. To confirm autophagy, the expression of autophagy-related proteins was investigated and it was revealed that Apigenin caused increase of Beclin-1 and LC3-II and suppression of p62 expression. However, no effects were found on the expression of LC3-I and Vps34 (Figure 5). The fact that Apigenin also induces apoptosis was validated by PI staining which showed apparent changes in the nuclear morphology of the HT-29 cells (Figure 6). The increased expression of Bax and decreased expression of the Bcl-2 in HT-29 cells further confirmed the activation of programmed cell death (Figure 7).

Inhibition of mTOR/PI3K/AKT signalling pathway by Apigenin

Apigenin-treated cells were also used for investigation of the effect of Apigenin on the mTOR/PI3K/AKT signalling pathway. It was found that Apigenin treatment resulted in dose-dependent reduction in the expression of p-mTOR, p-PI3K and p-AKT, while no apparent effect was seen on the expression of mTOR, PI3K and AKT (Figure 8).
Apigenin effects on cisplatin-resistant colon cancer cells

Hence, the results suggest that Apigenin blocks the mTOR/PI3K/AKT signalling pathway in HT-29 cells.

**Apigenin inhibits tumor growth in vivo**

The effects of Apigenin were also examined in vivo in xenografted mice models and the results indicated that Apigenin at the dosage of 35 mg/kg considerably suppressed the growth of the xenografted tumors. In addition, Apigenin inhibited the tumor weight and volume concentration-dependently (Figure 9A and B).

**Discussion**

Colon cancer is the second most prevalent type of malignancy in the world [15]. This cancer represents a problematic area due to inefficient treatment options and diagnosis at advanced stages [16]. In addition, the anticancer drugs that are being used for treating colon cancer are a source of important side effects which negatively impact the patient quality of life [17]. Molecules derived from plants have attained extraordinary attention in the recent past due to their comparatively lower toxic effects. Hence, the focus on the researchers across the globe is to identify and screen natural products against cancer cells for developing efficient drugs to target colon and other cancers [18]. In the present study, the antiproliferative effects of Apigenin were determined in cisplatin-resistant colon cancer cells.
cells. It was found that Apigenin treatment of HT-27 cells resulted in decline of proliferation rate. In the studies carried out previously, flavonoids have also been reported to inhibit the growth of cancer cells by triggering apoptosis and autophagy [19]. Autophagy and apoptosis are two processes that maintain the tissues’ homeostasis and help in the elimination of unwanted, harmful or cancer cells [20]. Herein, it was found that Apigenin activated both autophagy and apoptotic cell death of the HT-29 colon cancer cells. This was also associated with changes in the expression of autophagy as well as in the apoptosis-related protein expression. Previous studies have indicated that several of the anticancer molecules induce autophagy as well as apoptosis of cancer cells [20]. In cancer tissues/cells several of the signalling pathways are aberrantly activated and mTOR/PI3K/AKT is one such pathway which has been shown to play essential role in the proliferation of cancer cells [21]. In this study we found that Apigenin could inhibit the expression of p-mTOR, p-PI3K, and p-AKT in HT-29 cells concentration-dependently. Finally, it is imperative to evaluate the anticancer potential of such molecules in vivo in order to consider them as potential lead molecules. In the xenografted mice models it was found that Apigenin inhibits the growth of xenografted tumors, suggestive of its potent anticancer potential.

Conclusions

In conclusion, Apigenin exerts growth inhibitory effects on the cisplatin-resistant colon cancer cells by autophagy and apoptotic cell death. In addition, it also suppressed the tumor growth in vivo. Hence, Apigenin may prove to be a vital therapeutic agent and needs further in-depth investigation.

Conflict of interests

The authors declare no conflict of interests.

References

8. Choudhury D, Ganguli A, Dastidar DG, Acharya BR, Das...


